Roivant Sciences Ltd.
NASDAQ:ROIV
10.66 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 9.018 | 4.475 | 55.132 | 28.93 | 37.14 | 37.101 | 21.624 | 27.376 | 17.052 |
| Cost of Revenue
| 0.259 | 2.052 | 3.978 | 4.412 | 3.668 | 3.266 | 4.214 | 9.386 | 8.324 |
| Gross Profit
| 8.759 | 2.423 | 51.154 | 24.518 | 33.472 | 33.835 | 17.41 | 17.99 | 8.728 |
| Gross Profit Ratio
| 0.971 | 0.541 | 0.928 | 0.847 | 0.901 | 0.912 | 0.805 | 0.657 | 0.512 |
| Reseach & Development Expenses
| 141.595 | 142.349 | 133.208 | 120.902 | 123.717 | 131.984 | 125.133 | 131.857 | 125.533 |
| General & Administrative Expenses
| 141.545 | 202.881 | 148.519 | 0 | 197.282 | 0 | 156.19 | 0 | 0 |
| Selling & Marketing Expenses
| 0 | -1.094 | 0 | 0 | 0 | 0 | 156.19 | 0 | 0 |
| SG&A
| 141.545 | 201.787 | 148.519 | 169.616 | 197.282 | 164.355 | 156.19 | 120.299 | 163.523 |
| Other Expenses
| 0 | 0 | -110.387 | 0 | -5,348.41 | -538.958 | 12.5 | 0 | 0 |
| Operating Expenses
| 283.14 | 344.136 | 171.34 | 287.733 | -5,027.411 | -242.619 | 293.823 | 252.156 | 289.056 |
| Operating Income
| -274.381 | -341.713 | -120.186 | -266 | 5,060.883 | 276.454 | -276.413 | -234.166 | -280.328 |
| Operating Income Ratio
| -30.426 | -76.36 | -2.18 | -9.195 | 136.265 | 7.451 | -12.783 | -8.554 | -16.44 |
| Total Other Income Expenses Net
| 39.868 | 117.33 | 74.547 | 5,364.337 | 4,821.883 | -50.948 | -49.68 | 54.95 | -101.749 |
| Income Before Tax
| -234.513 | -224.383 | 70.145 | -191.453 | 5,098.337 | -327.361 | -326.093 | -179.216 | -382.077 |
| Income Before Tax Ratio
| -26.005 | -50.141 | 1.272 | -6.618 | 137.273 | -8.824 | -15.08 | -6.546 | -22.407 |
| Income Tax Expense
| -25.568 | 12.458 | 12.655 | -8.957 | 25.672 | 3.757 | 1.752 | -3.793 | 2.819 |
| Net Income
| 169.381 | -230.184 | 95.297 | -151.115 | 5,096.184 | -304.327 | -291.816 | -33.617 | -352.014 |
| Net Income Ratio
| 18.783 | -51.438 | 1.729 | -5.223 | 137.216 | -8.203 | -13.495 | -1.228 | -20.644 |
| EPS
| 0.23 | -0.31 | 0.13 | -0.188 | 6.37 | -0.4 | -0.38 | -0.045 | -0.49 |
| EPS Diluted
| 0.23 | -0.31 | 0.12 | -0.188 | 6.03 | -0.4 | -0.38 | -0.045 | -0.49 |
| EBITDA
| -274.381 | -222.565 | -179.072 | 5,113.166 | -310.831 | -311.342 | -309.722 | -163.132 | -305.421 |
| EBITDA Ratio
| -30.426 | -49.735 | 1.604 | -6.19 | 137.673 | -8.424 | -14.323 | -5.959 | -21.503 |